ClinicalTrials.gg
RecruitingNCT07303114DepVIHUpdated Jan 5, 2026

Missed Opportunities for HIV Screening in General Practice

An observational study in HIV Infections, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Planned enrollment
50th of 59
50 · median 200
Started
2025
with 3 others
Observational
59 of 278
13 open now
Primary completion
2026-07
later than 15 of 26 live
Registered
275th of 278
by date
Lead sponsor
7 of 278
University Hospital, Strasbourg, France

Among the 278 studies in HIV Infections with a site in France, this one is the 50th largest by planned enrollment of the 59 observational ones that give a count, is one of 4 that started in 2025, is one of 59 observational ones, reaches primary completion later than 15 of the 26 other live ones, and was the 275th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the barriers to testing.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV infections
  • HIV Testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult subject (≥18 years) diagnosed with HIV infection between January 1, 2021, and July 30, 2024

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subject (≥18 years)
  • diagnosed with infection between January 1, 2021, and July 30, 2024

Exclusion criteria

Exclusion Criteria:

-Subject who arrived in France in the year preceding or during the period between January 1, 2024, and July 30, 2024.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Presence or absence of clinical signs suggestive of HIV infection

    This is a retrospective analysis of data on the presence or absence of clinical signs suggestive of HIV infection during the year preceding diagnosis

    Time frame: 1 year preceding HIV diagnosis

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jul 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07303114
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Apr 14, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

baptiste Hoellinger, MD
Contact
baptiste.hoellinger@chru-strasbourg.fr
33 3 69 55 05 45

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion